Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 625-631

  Verschraegen, C F ^a   Levy, T ^a   Kudelka, A P ^a   Llerena, E ^a   Ende, K ^a   Freedman, R S ^a   Edwards, C L ^a   Hord, M ^a   Steger, M ^a   Kaplan, A L ^a   Kieback, D ^a   Fishman, A ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN;

ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 0031037244     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.625     Document Type: Article

References (51)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45:48-30, 1995
2. Disaia PJ, Creasman WT: Invasive cervical cancer, in Disaia PJ, Creasman WT (eds): Clinical Gynecologic Oncology. St. Louis, MO, Mosby, 1993, pp 58-125
3. Alberts DS, Garcia D, Mason-Liddil N: Cisplatinum in advanced cancer of the cervix: An update. Semin Oncol 18:11-24, 1991
4. Omura GA: Current status of chemotherapy for cancer of the cervix. Oncology 6:27-32, 1992
5. Wall ME, Wani MC, Cook CE: Plant antitumor agents. I. The isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888-3890, 1966
6. Li LH, Fraser TJ, Olin EJ, et al.: Action of camptothecin on mammalian cells in cultures. Cancer Res 32:2643-2650, 1972
7. Drewinko B, Freireich EJ, Gottlieb JA: Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34:747-750, 1974
8. Gallo RC, Whang-Peng J, Adamson RH: Studies on the antitumor activity, mechanism of action and cell cycle effects of camptothecin. J Natl Cancer Inst 46:789-795, 1971
9. Muggia FM, Creaven PJ, Hansen HH, et al.: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880). Cancer Chemother Rep 56:515-521, 1972
10. Moertel CG, Schutt AJ, Reitmeier RJ, et al.: Phase II study of camptothecin (NSC 100880) in the treatment of advance gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972
11. Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC 100880). Cancer Chemother Rep 56:103-105, 1972
12. Schaeppi V, Fleischman RW, Cooney DA: Toxicity of camptothecin (NSC 100880). Cancer Chemother Rep 58:25-36, 1974
13. Kunimoto T, Nitta K, Tanaka T, et al.: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
14. Matsuzaki T, Yokokura T, Mutai M.,et al.: Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:71-74, 1988
15. Nitta K, Yokokura T, Sawada S, et al.: Antitumor activity of a new derivative of camptothecin, in: Recent Advances in Chemotherapy. Tokyo, Japan, Tokyo Press, 1985, pp 28-30
16. Wang JC: DNA topoisomerases: Why so many? J Biol Chem 6:6659-6662, 1991
17. Champoux J: Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA 73:3488-3491, 1976
18. Lynn RM, Bjornsti MA, Caron PR, et al.: Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of saccharomyces cerevisiae DNA topoisomerase-I. Proc Natl Acad Sci USA 86:3559-3563, 1989
19. Liu LF, D'arpa P: Topoisomerase-targeting antitumor drugs: Mechanisms of cytotoxicity and resistance, in DeVita V, Hellman S, Rosenberg S (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1992, pp 79-89
20. Hsiang YH, Liu LF, Wall ME, et al.: DNA topoisomerase-I mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49:4385-4389, 1989
21. Chen AY, Liu LF: Mechanisms of resistance to topoisomerase inhibitors. Cancer Treatment Res 73:263-281, 1994
22. Ohno R, Okada K, Masaoka T, et al.: An early phase II study of CPT-11: A new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990
23. Negoro S, Fukuoka M, Niitani H, et al.: An early phase II study of CPT-11, a new camptothecin derivative, in small cell lung cancer. Proc Am Soc Clin Oncol 10:241, 1991 (abstr)
24. Masuda N, Fukuoka M, Kusunoki Y, et al.: CPT-11: A new derivative of camptothecin, for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
25. Fukuoka M, Niitani H, Suzuki A, et al.: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992
26. Masuda N, Fukuoka M, Kudoh S, et al.: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12:90-96, 1994
27. Okamoto H, Nagatomo A, Kunitoh H, et al.: A combination phase I-II study of carboplatin/irinotecan plus G-CSF with the Calvert equation in patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 14, A1150, 1995 (abstr)
28. Shimada Y, Yoshino M, Wakui A, et al.: CPT-11 gastrointestinal cancer study group. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
29. Futasuki K, Wakui A, Nakao I, et al.: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Gan To Kagaku Ryoho 21:1033-1038, 1994
30. Clavel M, Mathieu-Boue A, Dumortier A: Phase I study of CPT-11 administered as a daily infusion for 3 consecutive days. Proc Am Assoc Cancer Res 33:262, 1992 (abstr)
31. Takeuchi S, Takamizawa H, Takeda Y, et al.: An early phase II study of CPT-11 in gynecologic cancers. Research group of CPT-11 in gynecologic cancers. Gan To Kagaku Ryoho 18:579-584, 1991
32. Takeuchi S, Dobashi K, Fujimoto S, et al.: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gynecologic cancers. Gan To Kagaku Ryoho 18:1681-1689, 1991
33. Mori H, Itoh N, Kondoh H, et al.: Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative. Eur J Cancer 28:613-617, 1992
34. Saltz L, Kanowitz J, Kemeny N, et al.: Phase I trial of irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 14:A1546, 1995 (abstr)
35. Sugiyama T, Takeuchi S, Noda K, et al.: Phase I study of irinotecan (CPT-11) in combination with cisplatin in cervical cancer. Proc Am Soc Clin Oncol 13:A856, 1994 (abstr)
36. Takeuchi S, Noda K, Yakuhiji M, et al.: Late phase II study of CPT-11, a topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 11:A708, 1992 (abstr)
37. Kavanagh JJ, Kudelka AP, Edwards CL, et al.: CPT-11 (irinotecan): Phase II study in refractory squamous cell carcinoma of cervix. Proc Am Assoc Cancer Res 35:A1397, 1994 (abstr)
38. Chevallier B, Lhomme C, Dieras V, et al.: Phase II trial of CPT-11 in advanced cervical carcinoma. Proc Am Soc Clin Oncol 14:267, 1995 (abstr)
39. Peto J: The calculation and interpretation of survival curves, in Buyse M, Staquet M, Sylvester R (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University Press, 1984, pp 361-368
40. Breslow N: Comparison of survival curves, in Buyse M, Staquet M, Sylvester R (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University Press, 1984, pp 381-406
41. Perez CA, Kurman RJ, Stehman FB, et al.: Uterine cervix, in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology. Philadelphia, PA, Lippincott, 1992, pp 591-662
42. Souhami L, Gil RA, Allan SE, et al.: A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 9:970-977, 1991
43. Cardenas J, Olguin A, Figueroa F, et al.: Randomized neoadjuvant chemotherapy in cervical stage IIB PEC + RT versus RT. Proc Am Soc Clin Oncol 10:620, 1991 (abstr)
44. Chauvergne J, Rohart J, Heron JF, et al.: Randomized phase III trial of neoadjuvant chemotherapy (CT) and radiotherapy (RT) versus RT in stage IIB, III carcinoma of the cervix: A cooperative study of the French Oncology Centers. Proc Am Soc Clin Oncol 7:524, 1988 (abstr)
45. Tatersall MHN, Ramirez C, Coppleson MA: A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs radiotherapy alone in patients with locally advanced cervical cancer. Int J Gynecol Oncol 2:244-251, 1992
46. Itoh K, Takada M, Kudo S, et al.: Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines demonstrated by computer analysis. Lung Cancer 7:124-127, 1991
47. Noda K, Takeuchi S, Yakushiji M, et al.: Late phase II study of CPT-11, new camptothecin derivative, in cervical and ovarian carcinoma. Proc World Congress Gynecol Obstet 13:279, 1991 (abstr)
48. Andoh T, Ishii K, Suzuki Y, et al.: Characterization of a mammalian mutant with camptothecin-resistant DNA topoisomerase-I. Proc Natl Acad Sci USA 84:5565-5569, 1987
49. Zwelling LA, Kohn KW: Mechanism of action of cisdichlorodiammineplatinum (II). Cancer Treat Rep 63:1439-1444, 1979
50. Negoro S, Fukuoka M, Masuda N, et al.: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991
51. Gottlieb JA, Drewinko B: Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59:621-628, 1975